Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

ard of care regimen for each genotype. Preliminary safety and antiviral activity data from the 4-week combination treatment period are anticipated during the third quarter of 2008.

"Based on our pharmacokinetic modeling, we believe that the R7128 1000mg BID combination dosing regimen in Cohort 3 may be able to achieve similar antiviral responses as were demonstrated with R7128 1500mg BID in Cohort 2," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "Cohort 4 will be the first administration of R7128 in patients with HCV genotypes 2 or 3, and thus will serve as proof-of-concept for this population who we believe represent an area of great unmet medical need. If R7128 shows activity in HCV genotype 2 or 3 patients, this would demonstrate a distinct clinical attribute of nucleoside polymerase inhibitors."

Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from a Phase 1 oral single ascending dose study of R7128 in 46 healthy male volunteers showed that R7128 was generally well tolerated with no serious adverse events in doses up to 9000 mg.

In a Phase 1 study, R7128 demonstrated potent, dose-dependent antiviral activity across four genotype 1 prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstra
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 Insights- ... seamlessly connects people, technologies and care protoc ols across ... and the cost of healthcare delivery   ... presence at  ESC Congress 2015 , where the company is ... EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology with ...
(Date:8/27/2015)... Aug. 27, 2015 Biosimilars are not ... the U.S. Food and Drug Administration (FDA) for ... in its draft guidance issued today. The FDA,s ... proposes distinguishable names, calling for biological products to ... suffix. This proposal reflects the agency,s thinking that ...
(Date:8/27/2015)... Women Grow , the fastest-growing professional networking organization for women ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... sessions. CWCBExpo in LA will take place September 16-18, 2015 ... in Los Angeles, CA , and is ... marijuana industry. The Women Grow tracks at ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... , , , THOUSAND ... AMGN ) today announced that new data will be presented ... Prolia(TM) (denosumab) at the 2009 American Society for Bone and ... 2009. Prolia currently is being evaluated by regulatory bodies ...
... LEVADEX Analysis Shows Potential to ... Migraine is a common, debilitating ... United States, according to the,National Headache Foundation. Limitations of ... migraines, include slow onset of,significant pain relief between 45 ...
Cached Medicine Technology:Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 2Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 3Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 4Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 5Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 6Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 7Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting 8MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS 2
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 ... contains 15 seconds of unique footage that users can shrink and stretch in the ... and more. Users can customize color, brightness, scale, speed, range, and flare attributes with ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... the student experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 ... This is the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, ...
(Date:8/28/2015)... ... , ... An article published August 19th by the LA Times ... to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior pizza ... the current process, having already gone on for over a year, is taking much ...
(Date:8/28/2015)... ... 28, 2015 , ... The 6th Annual Survivor in the City, Chicago ... yet another accolade to its cadre of widespread support—an official letter of support and ... of the medical community and the University of Illinois at Chicago’s Department of Neurosurgery, ...
(Date:8/28/2015)... ... 28, 2015 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices, recently released Visio Stencils for the following product ... Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... Online Community and Collaboration Platform is Gaining ... Significant Usage in the ... GoLightly, Inc., a market,leader in delivering effective and ... software solutions for corporations and,membership organizations, is pleased ...
... LDG ) today reported preliminary total retail drug,store sales for the five-week and nine-week periods ended April 3, 2008., , ... Periods ended April 3, 2008, ... Month Quarter to Date (Dollars in millions) ... (9 weeks), Total retail drug store sales ...
... Inc. (Nasdaq: LMAT ) today announced the ... American Sales, to pursue other,business opportunities and the ... American Sales., Mr. Linden has approximately six ... joined LeMaitre Vascular in July 2002 as a ...
... July,6, 2006, Current Technology Corporation (the "Company") announced that,Keith ... Chief Executive,Officer, for nominal consideration, options ("Options") to purchase ... personal holdings, under the,following terms and conditions:, ... option -- 3,000,000; ii) exercise price ...
... on Saturday, April 12th at the ... Helen Mills Theatre in NYC, NEW YORK, ... a benefit concert on Saturday,April 12th at the Helen Mills Theatre in ... One,s Personal: A,Concert to Stop ACD," is being hosted by the 3 ...
... males who bring them pebbles to build egg nests. ... flowers guarded by larger males. , New research ... resources will still attempt to trade sexual currency for ... of Michigan School of Public Health. , The exchange ...
Cached Medicine News:Health News:Healthcare Sector Benefits from Online Community 2Health News:Longs Reports Preliminary March Retail Drug Store Sales 2Health News:LeMaitre Vascular Announces Changes to Its Executive Management Team 2Health News:Keith Denner Extends Current Technology's Chairman and CEO Options 2Health News:Keith Denner Extends Current Technology's Chairman and CEO Options 3Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 3Health News:Just like penguins and other primates, people trade sex for resources 2
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Modular hip abduction system designed to provide superior fit, adjustability and functionality for optimum patient stability, comfort and compliance...
... Stabilizer Abduction and rotation ... revisions and fractures. Preset ... with adjustable flexion and ... Adjustabelt back panel. Available ...
... contact casting for the treatment of ... plantar surface of the foot. Other ... plantar fasciitis or other foot conditions ... even distribution of body weight on ...
Medicine Products: